Mevacor Rx-To-OTC Switch Needs More Study, Committees Advise
Executive Summary
J&J/Merck's proposed nonprescription statin Mevacor Daily is likely to require more research to reach over-the-counter status after a joint FDA advisory committee found flaws in the sponsors' actual-use CUSTOM study